[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer

Inclusion Criteria: * Males ≥18 years of age. * Subjects provide signed informed consent and confirm that they are able and willing to comply with all protocol requirements. * Histologically confirmed adenocarcinoma of the prostate. * Radiologic evidence of local recurrence or new or progressive metastatic disease demonstrated on anatomical imaging (CT, or MRI), or whole-body bone scan within 4 weeks of Day 1. * At least 2 weeks must have elapsed between last anti-cancer treatment administration and the imaging day. Imaging day will be scheduled before initiation of new systemic therapy for recurrent and/or progressive metastatic disease * Screening clinical laboratory values within normal limits or judged not clinically significant by the investigator. Exclusion Criteria: * Subjects administered any radioisotope within five physical half-lives prior to study drug injection. * Subjects with any medical condition or other circumstances that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or completion.